Depo-Provera
(Medroxyprogesterone acetate)Phase 3Small molecule
Eli LillyIt's a hormone medication used to prevent pregnancy as a contraceptive injection, and it's also used to treat abnormal uterine bleeding and certain hormone-related conditions in women.[1] Depo-Provera is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]
Depo-Provera is one of 220 small molecule programs targeting Hyperplasia. It is currently in Phase 3.
9
Indications
31
Total Trials
5
Active Trials
219
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
103 competitors in Endometrial Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Femara
NovartisPhase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Megace
Bristol-Myers SquibbPhase 3
Lenvima
EisaiPhase 3
Lynparza
AstraZenecaPhase 3
Tecentriq
RochePhase 3
Trodelvy
GileadPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Endometrial Cancer4 trials
Treatment3 trials
Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause
Completed·—·Phase 3·NCT02943655·240 enrolled
Progestin-primed Ovarian Stimulation2 trials
Progesterone1 trial
20 more indications
HIV1 trial
Hormonal Birth Control and the Risk of Acquiring HIV
Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00006324·6,360 enrolled
Ovulation Induction1 trial
Endometrial Shedding Prior to Ovulation Induction Pilot Study
Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·Phase 4·NCT02340013·50 enrolled
Endometrial Hyperplasia without Atypia1 trial
Menorrhagia1 trial
Postmenopausal Women1 trial
Prostate Adenocarcinoma1 trial
Renal Cell Carcinoma1 trial
Hot flashes1 trial
Ovarian Stimulation1 trial
Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles
Completed·—·N/A·NCT05767086·297 enrolled
Chemotherapy-induced nausea and vomiting1 trial
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
Not yet recruiting·TThe First Affiliated Hospital of Xinxiang Medical College·Phase 3·NCT07124195·126 enrolled
Endometrial Carcinoma1 trial
Endometrioid Carcinoma1 trial
Hormone Replacement Therapy1 trial
Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00044837·120 enrolled
Endometrial Hyperplasia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Medroxyprogesterone acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]